Claims for Patent: 7,105,657

Summary for Patent: 7,105,657

Title:	Compositions and methods for inhibiting pancreatic cancer metastasis
Abstract:	Methods are provided for the inhibition of metastasis of cancer cells expressing MUC4, metastatic pancreatic cancer cells.
Inventor(s):	Batra; Surinder K. (Omaha, NE), Singh; Ajay P. (Omaha, NE), Moniaux; Nicolas (Omaha, NE)
Assignee:	Board of Regents of the University of Nebraska (Lincoln, NE)
Application Number:	10/291,151
Patent Claims:	1. An antisense nucleic acid molecule targeted to a nucleic acid molecule encoding human MUC4, wherein said antisense nucleic acid molecule is the complement of SEQ ID NO: 2. 2. The antisense nucleic acid molecule of claim 1, which is a DNA molecule. 3. The antisense nucleic acid molecule of claim 1, which is an RNA molecule. 4. The antisense nucleic acid of claim 1, which comprises at least one modified internucleoside linkage. 5. The antisense nucleic acid of claim 4, wherein said modified internucleoside linkage is a phosphorothioate linkage. 6. The antisense nucleic acid of claim 1, which comprises at least one modified sugar moiety. 7. The antisense nucleic acid of claim 6, wherein said modified sugar moiety is a 2'-o-methyloxymethyl sugar moiety. 8. The antisense of nucleic acid molecule claim 1, which comprises at least one modified base. 9. The antisense nucleic acid molecule of claim 8, wherein said modified base is a 5-methylcytosine. 10. A vector comprising a DNA which encodes the antisense nucleic acid molecule of claim 1. 11. A pharmaceutical preparation for inhibiting metastasis of cancer cells expressing MUC4, comprising the antisense nucleic acid molecule of claim 1 in a biologically compatible medium. 12. The pharmaceutical preparation of claim 11, wherein said antisense nucleic acid molecule comprises a modifications selected from the group consisting of a base, sugar, and lincage modification. 13. The pharmaceutical preparation of claim 11, further comprising at least one targeting agent for improving delivery of said antisense nucleic acid molecule to said cancer cells. 14. The pharmaceutical preparation of claim 13, wherein said at least one targeting agent comprises lipid. 15. The pharmaceutical preparation of claim 14, wherein said antisense nucleic acid molecule is encapsulated in an antibody-studded lipid vesicle. 16. The pharmaceutical preparation of claim 11, further comprising at least one additional anti-cancer agent. 17. The pharmaceutical preparation of claim 16, wherein said anti-cancer agent is selected from the group consisting of cisplatin, gemcitabine, carboplatin, herceptin, taxol, taxane derivatives, cyclophosphamide, methotrexate, vincristin, and etoposide. 18. A pharmaceutical preparation for inhibiting metastasis of cancer cells expressing MUC4, comprising the vector of claim 10 in a biologically compatible medium.

Details for Patent 7,105,657

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26